Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estradiol valerate + spironolactone
- Development stage
- Phase 4
- Lead developer
- Impacta Salud y Educación
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This feminizing hormone therapy regimen consists of a combination of estradiol valerate and spironolactone, specifically utilized in the Féminas implementation science study conducted by Asociación Civil Impacta Salud y Educación (IMPACTA) in Lima, Peru. The intervention was designed to provide gender-affirming medical care integrated with HIV prevention and treatment services for transgender women. Estradiol valerate, a synthetic estrogen, acts as an agonist at the estrogen receptor to induce feminization. Spironolactone, while primarily a mineralocorticoid receptor antagonist, is used in this context for its secondary role as an androgen receptor antagonist to suppress masculine secondary sexual characteristics. The study (NCT03757117) aimed to determine if providing these hormones alongside peer navigation could improve the HIV treatment cascade, particularly viral suppression, in this high-burden population.
- Other names
- feminizing hormone therapygender-affirming hormone therapyGAHT
02
Targets
AR (Adrenergic receptors)ESR1 (ERα)ESR2 (ERβ)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on estradiol valerate + spironolactone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estradiol valerate + spironolactone.